Genomed Spólka Akcyjna (WSE:GEN)

Market Cap	32.77M
Revenue (ttm)	23.01M
Net Income (ttm)	1.11M
Shares Out	1.32M
EPS (ttm)	0.84
PE Ratio	29.56
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,346
Average Volume	78
Open	27.60
Previous Close	28.00
Day's Range	24.60 - 27.60
52-Week Range	25.20 - 33.40
Beta	-0.02
RSI	22.35
Earnings Date	Feb 14, 2025

About Genomed Spólka Akcyjna

Genomed Spólka Akcyjna provides DNA analysis and congenital diseases diagnostic services in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company also offers the analysis of mutations responsible for congenital diseases in approximately 6,500 genes; and next-generation sequencing technology. In addition, it provides various types of DNA sequence analysis, including polymorphism analysis, and the sequencing of phage genetic material, ...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2007
• Employees: 44
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: GEN

Financial Performance

In 2023, Genomed Spólka Akcyjna's revenue was 22.48 million, an increase of 9.88% compared to the previous year's 20.46 million. Earnings were 926,248, an increase of 174.07%.